Calls to Restrict Prediction-Market Betting on Clinical Trial Results
Experts are urging regulators to curb wagering on the outcomes of medical trials through prediction markets.
A group of commentators argue that allowing bets on clinical-trial results creates conflicts of interest and could distort research incentives. They suggest that policy makers impose limits or bans on such prediction-market activities. The proposal highlights concerns about patient safety and the integrity of scientific data. Critics note that existing financial-technology frameworks may need new oversight to address these risks.
Why it matters
Betting on trial outcomes could bias research and affect patient safety.
In this story
prediction marketsclinical trialsbetting limitsresearch integrityregulatory oversightmedical researchfinancial regulation
